Autologous Stem Cell Transplantation Does Not Improve OS in Patients With Follicular Lymphoma
A partir d'une revue systématique de la littérature, cette méta-analyse évalue l'efficacité d'une greffe autologue de cellules souches dans le traitement des patients adultes atteints d'un lymphome folliculaire
High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), for previously untreated patients with advanced follicular lymphoma (FL) does not improve overall survival compared with conventional-dose chemotherapy alone, according to an online study published December 21 in the Journal of the National Cancer Institute.
Follicular lymphoma is the most common sub-type of non-Hodgkin’s lymphoma in North America, characterized by a long natural history, with multiple remissions and relapses following treatment. A number of chemotherapy regimens have been combined with ASCT in randomized clinical trials to treat follicular lymphoma, however, the effects of HDC-ASCT on event-free survival have varied.
In order to determine the impact of HDC-ASCT vs conventional-dose chemotherapy in adult patients …
Journal of the National Cancer Institute , communiqué de presse, 2011